[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337832-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337832-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","molecular-landscape-of-borderline-ovarian-tumours-a-systematic-review","Molecular landscape of borderline ovarian tumours - A systematic review","","Borderline ovarian tumours (BOTs) have molecular and genetic characteristics that separate them from other ovarian cancers. This systematic review analysed molecular changes reported in BOTs and assessed their clinical relevance for overall therapeutic strategy. Literature from 2000–2023 in PubMed, EMBASE, and Cochrane was reviewed, covering oncogenes, tumour suppressor genes, adhesion molecules, proteins, and glycoproteins, alongside microsatellite instability and loss of heterozygosity. Findings support molecular analysis for identifying carcinogenic mutations and advancing targeted therapy, while highlighting remaining needs for prognostic and extraneous-disease relationships.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/molecular-landscape-of-borderline-ovarian-tumours-a-systematic-review/337832/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/molecular-landscape-of-borderline-ovarian-tumours-a-systematic-review/337832.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the systematic review on borderline ovarian tumours?","Question",{"text":63,"@type":64},"To analyse the spectrum of molecular changes found in BOTs and discuss their significance in the context of the overall therapeutic approach.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which databases and time range were included in the review?",{"text":68,"@type":64},"Articles published between 2000 and 2023 were included from PubMed, EMBASE, and Cochrane.",{"name":70,"@type":61,"acceptedAnswer":71},"What kinds of molecular alterations were covered for BOTs in the review?",{"text":72,"@type":64},"The review covered oncogenes, tumour suppressor genes, adhesion molecules, proteins and glycoproteins, as well as microsatellite instability and loss of heterozygosity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337832,1790195548,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Review Article  \nPawel Sadlecki*, Malgorzata Walentowicz-Sadlecka  \nMolecular landscape of borderline ovarian tumours: A systematic review  \n[https://doi.org/10.1515/med-2024-0976](https://doi.org/10.1515/med-2024-0976)  \nreceived January 30, 2024; accepted May 5, 2024  \nAbstract: Borderline ovarian tumours (BOTs) show intriguing characteristics distinguishing them from other ovarian tumours. The aim of the systematic review was to analyse the spectrum of molecular changes found in BOTs and discuss their signiﬁcance in the context of the overall therapeutic approach. The systematic review included articles published between 2000 and 2023 in the databases: PubMed, EMBASE, and Cochrane. After a detailed analysis of the available publications, we qualiﬁed for the systematic review: 28 publications on proto-oncogenes: BRAF, KRAS, NRAS, ERBB2, and PIK3CA, 20 publications on tumour suppressor genes: BRCA1/2, ARID1A, CHEK2, PTEN, 4 on adhesion molecules: CADM1, 8 on proteins: B-catenin, claudin-1, and 5 on glycoproteins: E-Cadherin. In addition, in the further part of the systematic review, we included eight publications on microsatellite instability and three describing loss of heterozygosity in BOT. Molecular changes found in BOTs can vary on a caseby-case basis, identifying carcinogenic mutations through molecular analysis and developing targeted therapies represent signiﬁcant advancements in the diagnosis and treatment of ovarian malignancies. Molecular studies have contributed signiﬁcantly to our understanding of BOT pathogenesis, but substantial research is still required to elucidate the relationship between ovarian neoplasms and extraneous disease, identify accurate prognostic indicators, and develop targeted therapeutic approaches.  \nKeywords: borderline ovarian tumours, molecular features, mutations, genetic mutations, BRAF, KRAS, NRAS, ARID1A,  \n􀀁􀀁  \n* Corresponding author: Pawel Sadlecki, Medical Department, University of Science and Technology, Bydgoszcz, Poland; Department of Obstetrics and Gynecology, Regional Polyclinical Hospital, Grudziadz,  \nPoland, e-mail: [sadleckip@gmail.com](sadleckip@gmail.com)  \nMalgorzata Walentowicz-Sadlecka: Medical Department,  \nUniversity of Science and Technology, Bydgoszcz, Poland; Department of Obstetrics and Gynecology, Regional Polyclinical Hospital, Grudziadz,  \nPoland, [e-mail: walentowiczsadlecka@gmail.com](e-mail: walentowiczsadlecka@gmail.com)  \nCADM1, PIK3CA, CHEK2, CLAUDIN-1, ERBB2, loss of heterozygosity, PTEN, microsatellite instability, B-CATENIN, E-CADHERIN, BRCA 1, BRCA 2  \n1 Introduction  \nBorderline ovarian tumours (BOTs) exhibit intriguing characteristics that distinguish them from other ovarian tumours. Despite their unusual cellular structure and potential to spread, BOTs exhibit less aggressive behaviour than low- or high-grade serous ovarian cancers (LGSC and HGSC, respectively). This discrepancy has been observed since BOTs were ﬁrst described by Taylor in 1929 [1]. In 2003, BOTs were oﬃcially recognized as a distinct group, and their most recent classiﬁcation was published in 2014 by the World Health Organization [2]. BOTs occur in 1.8–4.8 per 100,000 women annually and comprise 10–20% of all epithelial ovarian cancers, with BOTs exhibiting a tendency towards higher prevalence within this broader group of cancers [3,4]. This unique type of non-invasive neoplasms is characterised by atypical growth of epithelial cells, nuclear atypia, and a moderatelevel of mitotic activity that places a particular type between benign tumours and invasive cancers [5]. Notably, BOTs do not exhibit destructive stromal invasion, which diﬀerentiates them from other types of ovarian neoplasms. Although BOTs do not display destructive stromal invasion, they can be associated with microinvasion, lymph node implantation, and non-invasive or invasive peritoneal implantation [5]. Generally, BOTs display molecular and genetic alterations similar to those found in LGSCs. In some cases, a gra","cbCaid6LHe1GT3Cw","https://ap.wps.com/l/cbCaid6LHe1GT3Cw","pdf",646105,17,"English","# Introduction\n# Management and surgical considerations","[{\"question\":\"What was the purpose of the systematic review on borderline ovarian tumours?\",\"answer\":\"To analyse the spectrum of molecular changes found in BOTs and discuss their significance in the context of the overall therapeutic approach.\"},{\"question\":\"Which databases and time range were included in the review?\",\"answer\":\"Articles published between 2000 and 2023 were included from PubMed, EMBASE, and Cochrane.\"},{\"question\":\"What kinds of molecular alterations were covered for BOTs in the review?\",\"answer\":\"The review covered oncogenes, tumour suppressor genes, adhesion molecules, proteins and glycoproteins, as well as microsatellite instability and loss of heterozygosity.\"}]","Molecular landscape of borderline ovarian tumours - A systematic review | PDF",1790020828,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8f027312f97d229af21f1df884fb5e14.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd9513c4096dc92a8c3619b0c98e3e7b.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a50308a4c1fb052ccb4cb3b2ba21578.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22c00294c1246e6ebd9caad4cc467134.webp",980,1306]